ERBB2 and ductal breast carcinoma in situ: Tumor biology plays a central role in this interpretation: in triple-negative and HER2-positive tumors with complete functional imaging response, persistent calcifications are more likely to reflect benign treatment-related changes, whereas in hormone receptor-positive disease, the possibility of residual non-enhancing DCIS remains clinically relevant.